Carlisle Reports Q4 Revenue of $1.13B, Exceeding Expectations
Reports Q4 revenue $1.13B, consensus $1.11B. Chris Koch, Chair, President and Chief Executive Officer, said: "Throughout 2025, despite continued headwinds in new construction and a complex economic environment, we continued to execute against our Vision 2030 strategy, and we remain very confident in our key long-term financial objective of delivering $40 of adjusted EPS. Over the course of the year, we made progress on all our key pillars of Vision 2030. We increased investments in innovation to develop new market-leading products. We enhanced our emphasis on the Carlisle Operating System and expanded automation in our factories to drive operational excellence. We added significant management talent and further elevated the Carlisle Experience to strengthen customer loyalty and service. And above all else, we continued to deliver on our commitment to being superior capital allocators. Carlisle's performance during 2025 adds to our history of resilience through the economic cycles and challenges we have faced over the years, such as the Covid pandemic. We delivered another solid year of cash flow, generating over $1 billion of operating cash flow, which continued to provide balance sheet optionality. As the M&A environment in 2025 was challenging, we turned a significant portion of that cash flow to share repurchases, as we continued to see this as a solid opportunity for capital deployment."
Trade with 70% Backtested Accuracy
Analyst Views on CSL
About CSL
About the author


- Investment Changes: Generation Investment Management, co-founded by Al Gore, exited two semiconductor companies in Q4.
- New Acquisitions: The firm invested in shares of a trending streaming provider during the same period.
- FDA Review Decision: The FDA's agreement to review Moderna's experimental mRNA flu vaccine reverses its earlier refusal, stunning Wall Street and the medical community, marking a significant advancement in vaccine development.
- Positive Market Reaction: Following the FDA review announcement, Moderna's shares rose over 6%, reflecting investor confidence in the company's future flu vaccine market potential and paving the way for its goal of breaking even by 2028.
- New Application Strategy: Moderna's revised regulatory approach seeks full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, addressing FDA criticisms of its trial design and enhancing the vaccine's market competitiveness.
- Changing Regulatory Environment: The FDA's decision highlights significant shifts in U.S. vaccine regulatory policies, particularly under the leadership of the new Secretary of Health and Human Services, with Moderna's application process facing stricter scrutiny, illustrating the complexities and challenges of vaccine regulation.

Stock Sale Announcement: Christian Koch, an officer at Carlisle Companies (CSL.U.S), plans to sell 36,260 shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $14.5 million.

- U.S. Stock Market Performance: Stock indexes in the U.S. closed mixed on Wednesday, indicating varied performance across different sectors.
- Index Movements: The S&P 500 rose by 0.53%, while the Dow Jones Industrial Average fell by 0.51%, and the Nasdaq Composite experienced a decline of 1.51%.
- Earnings Beat: Cirrus Logic reported third-quarter earnings of $2.97 per share, surpassing the analyst consensus estimate of $2.44 per share, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $580.620 million, exceeding the analyst consensus estimate of $533.890 million, demonstrating strong market demand and driving sustained performance growth.
- Stock Surge: Following the positive earnings report, Cirrus Logic's shares jumped 7.6% to $134.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: Cirrus Logic provided fourth-quarter sales guidance that is expected to exceed market estimates, further solidifying its competitive position in the semiconductor industry.
- Price Fluctuation Range: CSL's stock has a 52-week low of $293.43 and a high of $435.92, with the last trade at $385.55, indicating significant volatility over the past year and reflecting varying market expectations regarding its future performance.
- Dividend Stock Dynamics: The current price of CSL is above its 200-day moving average, suggesting a relatively strong performance among dividend stocks, which may attract more investors seeking stable income, thereby enhancing its market appeal.
- Market Sentiment Analysis: Although the current stock price is positioned in the middle of its 52-week range, perceptions of CSL may vary due to its dividend policy and future growth potential, necessitating investors to monitor relevant financial metrics for informed decision-making.
- Investor Focus: The fluctuations in CSL's stock price and its dividend performance could influence investment strategies, particularly in the context of seeking long-term stable returns, making the analysis of its price trends and market dynamics crucial.






